“Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing.
The present invention relates to a method for reducing the addictive andpsychotomimetic side effects of ketamine and enhancing the medical efficacy of ketamine. It is characterized by using ketamine in combination withmethylglycine derivatives for administration
3.Potential collaboration partner qualifications:
(1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
(2) better to have related experience and skills for developing The Technology
(3) better to have experience of international collaboration and clinical trial
(4) better to be ready to invest or be able to raise the funds
Please contact to Mr. Patrick Liu or Ms. Wen-Chuan Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206/33209, E-mail: email@example.com; firstname.lastname@example.org ) before Aug 4, 2020.
NHRI retains the right to modify and terminate this announcement.
For detailed status of The Technology, please contact to the case officer.